This article was originally published in The Gray Sheet
Firm expands claims for the accuDEXA by gaining 510(k) clearance to market the bone densitometer as an aid in determining fracture risk. In December, Schick received clearance to promote the device for assessment of bone mineral density ("The Gray Sheet" Dec. 8, I&W-11). Performed in the primary care physician-office setting, the accuDEXA scans a patient's middle finger to determine the relative risk of fracture in other bones
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.